Affluent Medical SA has completed the acquisitions of Caranx Medical and Artedrone, consolidating the three companies under a new name, Carvolix. The transaction was finalized with payments of €16.6 million and €11.4 million for Caranx Medical and Artedrone, respectively, paid entirely in Carvolix shares. As part of the strategic move, a €10 million first tranche of financing has been secured from Truffle Capital and Edwards Lifesciences at a subscription price of €2.34 per share, representing an 18.8% premium versus the last closing share price. The combined entity will focus on developing AI-driven mini-robots and biomimetic implants for interventional cardiology and stroke treatment, aiming to accelerate innovation and expand its addressable market. The first product launch, TAVIPILOT software, has already received FDA clearance and will be introduced in the US in early 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Affluent Medical SA published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: fr_reg_2269244_en), on February 02, 2026, and is solely responsible for the information contained therein.